Second-line chemotherapy in advanced pancreatic Carcinoma:: a multicenter survey of the gruppo oncologico italia meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
Second-line chemotherapy in advanced pancreatic Carcinoma:: a multicenter survey of the gruppo oncologico italia meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
复制标题
DOI：
10.1093/annonc/mdm240
复制
发表时间：
2007-01-01
影响因子：
50.5
通讯作者：
Colucci, G.
中科院分区：
文献类型：
--
作者：
Gebbia, V.;Maiello, E.;Colucci, G.
背景：在日常临床实践中，二线化疗（SLCT）经常用于吉西他滨一线化疗失败的晚期胰腺癌患者，没有坚实的科学支持。患者与方法：对42例患者进行回顾性调查。患者每两周一次接受标准FOLFOX4方案，直到病情进展或出现不可接受的毒性。结果：6例部分缓解（14%），16例稳定（38%），肿瘤生长控制率为57%。中位进展时间（TtP）为4个月（范围1-7个月），中位总生存期（OS）为6.7个月（范围2-9个月）。27例患者表现状态（PS）稳定，癌症相关症状主观改善。结论：本文数据支持FOLFOX4方案在胰腺腺癌患者的二线治疗中使用，但对于PS良好或对一线治疗反应良好的患者，应谨慎建议使用SLCT。
Background: In daily clinical practice second-line chemotherapy (SLCT) is frequently given to patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy without solid scientific support.Patients and methods: A retrospective survey was carried out including 42 patients. Patients received standard FOLFOX4 regimen biweekly until progression or unacceptable toxicity.Results: Six partial responses (14%) and 16 stabilizations (38%) were recorded for a tumor growth control rate of 57%. The median time to progression (TtP) was 4 months (range 1-7 months), and median overall survival (OS) was 6.7 months (range 2-9 months). A stabilization of performance status (PS) and a subjective improvement of cancer-related symptoms were recorded in 27 patients.Conclusions: Data presented in this paper support the use of FOLFOX4 regimen in the second-line treatment of adenocarcinoma of the pancreas patients, The use of SLCT, however, should be carefully proposed to patients with good PS or those who had a good response to first-line therapy.